Finance

Roche and Sanofi Push Pipelines as Earnings Move Shares Very Little

Roche and Sanofi posted full-year results that met expectations, with shares dipping under 1% in premarket trading. Both are leaning on pipelines to offset a looming patent cliff, and Roche guided 2026 profit growth to outpace sales growth at constant currencies.

📅 January 29, 2026
⏱️ 2 min read
Roche and Sanofi Push Pipelines as Earnings Move Shares Very Little

Key Takeaways

  • Roche and Sanofi posted full-year results that met expectations, with shares dipping under 1% in premarket trading.
  • Roche guidance targets high-single-digit adjusted EPS growth in 2026 at constant currencies, with profit growth outpacing sales.
  • Roche Q4 sales rose 8% led by Ocrevus and Tecentriq, while Sanofi Q4 sales rose 13% at constant currencies and EPS was €1.53.
  • Sanofi guided 2026 sales growth in the high single digits and announced a €1 billion share buyback, with Jefferies noting pipeline expansion as central to earnings.
  • Roche is pursuing obesity drug CT-388 with 22.5% weight loss over 48 weeks and has a Zealand Pharma partnership on petrelintide, while eyeing up to 19 new medicines by 2030.

People Involved

  • Thomas SchineckerCEO, Roche
  • Paul HudsonCEO, Sanofi
  • Michael LeuchtenJefferies analyst

Entities Involved

  • RocheSwiss pharmaceutical company
  • SanofiFrench pharmaceutical company
  • Zealand PharmaBiopharma partner for petrelintide

MarketMoodz Analysis

The results underscore how these global pharma giants are leaning on pipeline progress to justify valuations amid a looming patent cliff. Investors will be watching for Phase 3 milestones, obesity-drug developments, and any M&A signals that could accelerate revenue growth beyond core franchises.

Historically, patent cliffs have pressured revenue as blockbusters lose exclusivity; Roche’s plan to launch up to 19 new medicines by the end of the decade and Sanofi’s emphasis on Dupixent and vaccines reflect a shift toward diversified portfolios. The key near-term catalysts are Phase 3 data, regulatory milestones, and any strategic steps on deals or partnerships to keep growth trajectory intact.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial